A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer

Published:2022-09 Issue:3 Volume:21 Page:252-258
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Chuang Jeremy,Gong Jun,Li Sierra Min,Wang Chongkai,Fakih Marwan

Funder

Novartis Pharmaceuticals Corp

Novartis

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference27 articles.

1. Cancer Statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005;Cheng;Am J Clin Oncol,2011

3. Metastatic colorectal cancer: current state and future directions;Fakih;J Clin Oncol,2015

4. Randomized trial of TAS-102 for refractory metastatic colorectal cancer;Mayer;N Engl J Med,2015

5. Abstract 1637: The MEK/Erk pathway is required for PC3 cell survival following FdUMP[10]treatment;Gomes;Cancer Research,2010

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer treatment;Oncology in Clinical Practice;2024-02-05

2. Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells;Oncotarget;2023-10-04

3. Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal;Cancers;2023-09-29

4. New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer;Current Treatment Options in Oncology;2023-05-22